Search

New Role of Apolipoprotein E4 Variant in Alzheimer's Disease Suggests Possible Therapeutic Target

NEW ROLE OF APOLIPOPROTEIN E4 VARIANT IN ALZHEIMER'S DISEASE SUGGESTS POSSIBLE THERAPEUTIC TARGET

The apolipoprotein ApoE4 is a high-risk Alzheimer's gene that increases brain damage caused by another protein called Tau in Alzheimer's...

 
 
 
 
 
 
2 contrasting medtech approaches to deal with chronic pain and avoid opioids

2 CONTRASTING MEDTECH APPROACHES TO DEAL WITH CHRONIC PAIN AND AVOID OPIOIDS

Medtronic and SPR Therapeutics are treating chronic pain but while the former has adopted a permanent, implantable neuromodulation...

Eyeing a Comeback, Arrowhead Bets on New RNAi Delivery Tool

EYEING A COMEBACK, ARROWHEAD BETS ON NEW RNAI DELIVERY TOOL

Following a series of setbacks late last year, Arrowhead Pharmaceuticals, one of the companies trying to develop drugs using RNA interference,...

 
 
 
Disarm Launches With $30M From Atlas, AbbVie to Battle Neuro Disease

DISARM LAUNCHES WITH $30M FROM ATLAS, ABBVIE TO BATTLE NEURO DISEASE

The available drugs for neurodegenerative conditions like multiple sclerosis can only treat symptoms, or at best slow the disease's...

 
 
 

GRADDOCK: RAPID SIMULATION AND TAILORED RANKING FUNCTIONS FOR PEPTIDE-MHC CLASS I DOCKING

Abstract Motivation: The identification of T-cell epitopes has many profound translational applications in the areas of transplantation,...

 
 
 
Ex-Cubist CEO Bonney Emerges at Kaleido, Flagship's Latest Microbiome Startup

EX-CUBIST CEO BONNEY EMERGES AT KALEIDO, FLAGSHIP'S LATEST MICROBIOME STARTUP

Flagship Pioneering has been as active as any venture firm at funneling its investment dollars into microbiome drug developers. It's...

 
 
 
After Biogen Deal Fizzles, Rodin Bags $27M And Heads To First Trial

AFTER BIOGEN DEAL FIZZLES, RODIN BAGS $27M AND HEADS TO FIRST TRIAL

An option-to-buy deal, when one company agrees to buy another on prearranged terms after a series of milestones are met, doesn't always...

 
 
 
Bio Roundup: Phase 3 Fails, Shkreli Jailed, Moderna Flip-Flops & More

BIO ROUNDUP: PHASE 3 FAILS, SHKRELI JAILED, MODERNA FLIP-FLOPS & MORE

It was a week of realignments. President Trump, who used to be known as “The Donald” but now goes by “ Amnesty Don ,” kept up the parlay-voo...

 
 
 
Halozyme Inks $105M Bristol-Myers Partnership, Expands Roche Deal

HALOZYME INKS $105M BRISTOL-MYERS PARTNERSHIP, EXPANDS ROCHE DEAL

Halozyme Therapeutics has turned a method of delivering a drug more conveniently into partnerships with several large pharmaceutical...

 
 
 
Moderna Ends “Venture” Experiment, Dissolves Four Startups

MODERNA ENDS “VENTURE” EXPERIMENT, DISSOLVES FOUR STARTUPS

Moderna Therapeutics, the high-flying private company with a $1 billion war chest, is reversing course. Three years ago, it decided...

BridgeBio Bags $135M For “Hub and Spoke” Rare Disease Drug R&D

BRIDGEBIO BAGS $135M FOR “HUB AND SPOKE” RARE DISEASE DRUG R&D

Thousands of diseases have been traced to genetic origins, but the vast majority have no treatment at all. BridgeBio wants to reduce...